Johnson & Johnson’s Janssen has had biopharma operations in Ringaskiddy, Co. Cork for nearly 15 years. Now it has a new $350 million facility and added 200 jobs.
The official opening, which was announced by IDA Ireland, boosted the site’s size by 19,100 square meters (205,590 square feet).
“Our Ringaskiddy facility is an important part of our global manufacturing network and expanding our capabilities here will allow us to pursue innovative solutions …” Kathy Wengel, J&J’s chief global supply chain officer, said in a statement.
The company started on the €300 million project in 2017. The additions included expansion of an existing warehouse, laboratory and administration buildings, and expansion of the wastewater treatment plant to accommodate increased volumes.
At the time the company said the new plant would bolster capacity of APIs for drugs that treat “multiple myeloma, rheumatoid arthritis and Crohn’s disease.” While it didn’t specifically identify the products to be made there, J&J sells blockbuster Remicade for rheumatoid arthritis and Crohn’s disease, as well as Simponi for treating rheumatoid arthritis and Stelara for treating Crohn’s disease.
According to a new forecast from GlobalData, Stelara is expected to be the ninth-best selling drug globally in 2025 with $7.5 billion in sales.
By Eric Palmer
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
